{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:59:31Z","timestamp":1792839571682,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jtha.2024.05.023","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T05:52:00Z","timestamp":1717134720000},"page":"2653-2669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-919X","authenticated-orcid":false,"given":"Stephanie","family":"Carlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gendron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Hern\u00e1ndez-Gea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Siegal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Stanworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton","family":"Lisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara N.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.05.023_bib1","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jth.15239","article-title":"The concept of rebalanced hemostasis in patients with liver disease: communication from the ISTH SSC working group on hemostatic management of patients with liver disease","volume":"19","author":"Lisman","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib2","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1053\/j.gastro.2009.08.045","article-title":"An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis","volume":"137","author":"Tripodi","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtha.2024.05.023_bib3","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","article-title":"Thrombocytopenia associated with chronic liver disease","volume":"48","author":"Afdhal","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/hep.28628","article-title":"Coagulation parameters and major bleeding in critically ill patients with cirrhosis","volume":"64","author":"Drolz","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2024.05.023_bib5","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1055\/a-1667-7293","article-title":"Prevalence of bleeding and thrombosis in critically ill patients with chronic liver disease","volume":"122","author":"Ow","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/HEP.0000000000000349","article-title":"The evolving knowledge on primary hemostasis in patients with cirrhosis: a comprehensive review","volume":"79","author":"Zanetto","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2024.05.023_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.21231","article-title":"Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity","volume":"44","author":"Lisman","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2024.05.023_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1055\/s-0040-1715102","article-title":"Thrombin generation and cirrhosis: state of the art and perspectives","volume":"46","author":"Lebreton","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib9","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.jtha.2023.03.017","article-title":"In\u00a0vivo generation of thrombin in patients with liver disease without apparent evidence of activation of the intrinsic or extrinsic pathway of coagulation","volume":"21","author":"Elvers","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1055\/s-0040-1718924","article-title":"Fibrinolysis in patients with liver disease","volume":"47","author":"von Meijenfeldt","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1478-3231.2010.02358.x","article-title":"Low-molecular-weight heparin in patients with advanced cirrhosis","volume":"31","author":"Bechmann","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jtha.2024.05.023_bib12","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/cc4952","article-title":"Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study","volume":"10","author":"Rommers","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.jtha.2024.05.023_bib13","first-page":"1336","article-title":"Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients","volume":"59","author":"Haas","year":"2005","journal-title":"J\u00a0Trauma"},{"key":"10.1016\/j.jtha.2024.05.023_bib14","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients\u00a0with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.05.023_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhepr.2019.02.006","article-title":"Anticoagulation in the cirrhotic patient","volume":"1","author":"Turco","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jtha.2024.05.023_bib16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/CIRCOUTCOMES.113.000817","article-title":"Stratifying the risks of oral anticoagulation in patients with liver disease","volume":"7","author":"Efird","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jtha.2024.05.023_bib17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.05.023_bib18","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.05.023_bib19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2024.05.023_bib20","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.jtha.2024.05.023_bib21","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment","volume":"48","author":"Stangier","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.05.023_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.05.023_bib23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40268-021-00359-y","article-title":"Apixaban pharmacokinetics and pharmacodynamics in subjects with mild or moderate hepatic impairment","volume":"21","author":"Frost","year":"2021","journal-title":"Drugs R D"},{"key":"10.1016\/j.jtha.2024.05.023_bib24","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/liv.14992","article-title":"Safety of direct oral anticoagulants in patients with advanced liver disease","volume":"41","author":"Semmler","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jtha.2024.05.023_bib25","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/jcph.550","article-title":"An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics","volume":"55","author":"Mendell","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.05.023_bib26","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1182\/blood.2020005319","article-title":"Anticoagulant activity of edoxaban in patients with cirrhosis","volume":"136","author":"Bos","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.023_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.023_bib28","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet\u00a0alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.05.023_bib29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.14309\/ajg.0000000000001627","article-title":"American College of Gastroenterology-Canadian Association of Gastroenterology clinical practice guideline: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period","volume":"117","author":"Abraham","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jtha.2024.05.023_bib30","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2024.05.023_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jth.15562","article-title":"Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: guidance from the SSC of the ISTH","volume":"20","author":"Roberts","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68304-8","article-title":"Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study","volume":"10","author":"Maura","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2024.05.023_bib33","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/MEG.0000000000001315","article-title":"Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: a meta-analysis","volume":"31","author":"Chokesuwattanaskul","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib34","article-title":"Liver disease as a predictor of new-onset atrial fibrillation","volume":"7","author":"Huang","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jtha.2024.05.023_bib35","article-title":"Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?","volume":"6","author":"Kuo","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jtha.2024.05.023_bib36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/apt.17368","article-title":"Review article: diagnosis, pathophysiology and management of atrial fibrillation in cirrhosis and portal hypertension","volume":"57","author":"Vandenberk","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jtha.2024.05.023_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819832237","article-title":"Gastrointestinal and liver diseases and atrial fibrillation: a review of the literature","volume":"12","author":"Long","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jtha.2024.05.023_bib38","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.jacc.2016.08.074","article-title":"Alcohol and atrial fibrillation: a sobering review","volume":"68","author":"Voskoboinik","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2024.05.023_bib39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cld.2022.03.004","article-title":"Alpha-1 antitrypsin deficiency liver disease","volume":"26","author":"Suri","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jtha.2024.05.023_bib40","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/CIRCEP.110.960401","article-title":"Iron overload decreases CaV1.3-dependent L-type Ca2+ currents leading to bradycardia, altered electrical conduction, and atrial fibrillation","volume":"4","author":"Rose","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jtha.2024.05.023_bib41","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jacc.2009.12.075","article-title":"Cirrhotic cardiomyopathy","volume":"56","author":"Zardi","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2024.05.023_bib42","article-title":"Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy","volume":"3","author":"Iwakiri","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jtha.2024.05.023_bib43","doi-asserted-by":"crossref","first-page":"662","DOI":"10.4254\/wjh.v7.i4.662","article-title":"Arrhythmia risk in liver cirrhosis","volume":"7","author":"Mozos","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib44","first-page":"11","article-title":"Hepatorenal syndrome","volume":"28","author":"Ng","year":"2007","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.jtha.2024.05.023_bib45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.dld.2018.12.001","article-title":"Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: a systematic review and meta-analysis","volume":"51","author":"Chokesuwattanaskul","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jtha.2024.05.023_bib46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.31264","article-title":"Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation","volume":"73","author":"Serper","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2024.05.023_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2022.101952","article-title":"Thromboembolism and bleeding in patients with atrial fibrillation and liver disease - a nationwide register-based cohort study: thromboembolism and bleeding in liver disease","volume":"46","author":"Steensig","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jtha.2024.05.023_bib48","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/HEP.0000000000000580","article-title":"The liver meeting: Boston, Massachusetts Nov 10-14, 2023","volume":"78","author":"Ayoub","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2024.05.023_bib49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jacc.2019.04.061","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation and history of liver disease","volume":"74","author":"Qamar","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2024.05.023_bib50","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.jacc.2019.04.052","article-title":"Direct oral anticoagulants in patients with atrial fibrillation and liver disease","volume":"73","author":"Lee","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2024.05.023_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13397","article-title":"CAR. Direct oral anticoagulants and advanced liver disease: a systematic review and meta-analysis","volume":"51","author":"Menichelli","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jtha.2024.05.023_bib52","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.122.060687","article-title":"Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study","volume":"147","author":"Lawal","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.05.023_bib53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2024.03.024","article-title":"Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: a multinational cohort study","volume":"237","author":"Douros","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.05.023_bib54","doi-asserted-by":"crossref","first-page":"265","DOI":"10.5114\/ceh.2023.130605","article-title":"Assessment of the efficiency and safety of anti-coagulation therapy in patients with liver cirrhosis and atrial fibrillation","volume":"9","author":"Baylo","year":"2023","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib55","article-title":"Prescribing trends of oral anticoagulants in US patients with cirrhosis and nonvalvular atrial fibrillation","volume":"12","author":"Simon","year":"2023","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jtha.2024.05.023_bib56","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/bcp.15046","article-title":"Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease","volume":"88","author":"Douros","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.05.023_bib57","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1053\/j.gastro.2021.08.015","article-title":"AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis","volume":"161","author":"O\u2019Shea","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtha.2024.05.023_bib58","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.05.023_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2024.05.023_bib60","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/europace\/euad004","article-title":"Left atrial appendage closure device outcomes among cirrhosis patients with atrial fibrillation: a United States national cohort study","volume":"25","author":"Mir","year":"2023","journal-title":"Europace"},{"key":"10.1016\/j.jtha.2024.05.023_bib61","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.hrthm.2022.04.009","article-title":"Liver cirrhosis is independently associated with increased in-hospital mortality in patients undergoing left atrial appendage occlusion device implantation","volume":"19","author":"Thotamgari","year":"2022","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jtha.2024.05.023_bib62","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1572-0241.2006.00588.x","article-title":"Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism","volume":"101","author":"Northup","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jtha.2024.05.023_bib63","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1002\/hep.32019","article-title":"Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nation-wide cohort study","volume":"74","author":"Jepsen","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2024.05.023_bib64","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/ajg.2008.34","article-title":"Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study","volume":"104","author":"S\u00f8gard","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jtha.2024.05.023_bib65","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1160\/TH16-06-0450","article-title":"The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis","volume":"117","author":"Ambrosino","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib66","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/jth.15829","article-title":"Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: guidance from the SSC of the ISTH","volume":"20","author":"Roberts","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib67","series-title":"Venous thromboembolic diseases: diagnosis, management and thrombophilia testing guideline","year":"2020"},{"key":"10.1016\/j.jtha.2024.05.023_bib68","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.023_bib69","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.023_bib70","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.023_bib71","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.023_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102293","article-title":"Venous thromboembolism, chronic liver disease and anticoagulant choice: effectiveness and safety of direct oral anticoagulants versus warfarin","volume":"8","author":"Lawal","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib73","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib74","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1160\/TH16-10-0781","article-title":"Incidence rates and case fatality rates of portal vein thrombosis and Budd\u2013Chiari syndrome","volume":"117","author":"Ageno","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib75","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2021.04.029","article-title":"Current knowledge and management of portal vein thrombosis in cirrhosis","volume":"75","author":"Senzolo","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib76","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-0038-1676981","article-title":"Incidence and recurrence of portal vein thrombosis in cirrhotic patients","volume":"119","author":"Violi","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib77","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jhep.2021.07.020","article-title":"Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors","volume":"75","author":"Turon","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib78","article-title":"Trends and the course of liver cirrhosis and its complications in Germany: nationwide population-based study (2005 to 2018)","volume":"12","author":"Gu","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jtha.2024.05.023_bib79","series-title":"Portal hypertension","article-title":"Anatomy of the portal vein system and hepatic vasculature","author":"Okudaira","year":"1991"},{"key":"10.1016\/j.jtha.2024.05.023_bib80","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0049-3848(84)90224-X","article-title":"Flow through a venous valve and its implication for thrombus formation","volume":"36","author":"Karino","year":"1984","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.05.023_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100998","article-title":"Gut dysbiosis, endotoxemia and clotting activation: a dangerous trio for portal vein thrombosis in cirrhosis","volume":"57","author":"Violi","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2024.05.023_bib82","first-page":"800","article-title":"The pathophysiology of portal vein thrombosis in cirrhosis: getting deeper into Virchow\u2019s triad","volume":"11","author":"Anton","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.05.023_bib83","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.32169","article-title":"Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus","volume":"75","author":"Driever","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2024.05.023_bib84","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1038\/s41598-020-59526-x","article-title":"The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli","volume":"10","author":"Chernysh","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2024.05.023_bib85","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jhep.2009.03.013","article-title":"Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development","volume":"51","author":"Zocco","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib86","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/liv.14121","article-title":"Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: a prospective study","volume":"39","author":"Noronha Ferreira","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jtha.2024.05.023_bib87","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.27546","article-title":"Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study","volume":"61","author":"Nery","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2024.05.023_bib88","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/lt.25630","article-title":"Development of a model to predict portal vein thrombosis in liver transplant candidates: the portal vein thrombosis risk index","volume":"25","author":"Gaballa","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jtha.2024.05.023_bib89","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/liv.13500","article-title":"Decreased portal vein velocity is predictive of the development of portal vein thrombosis: a matched case-control study","volume":"38","author":"Stine","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jtha.2024.05.023_bib90","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/MEG.0000000000000325","article-title":"De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the model for end-stage liver disease scoring system","volume":"27","author":"Abdel-Razik","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib91","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/lt.24134","article-title":"Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis","volume":"21","author":"Stine","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jtha.2024.05.023_bib92","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1471-230X-12-114","article-title":"Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients","volume":"12","author":"Ayala","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jtha.2024.05.023_bib93","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/17474124.2019.1651644","article-title":"Visceral fat is associated with cirrhotic portal vein thrombosis","volume":"13","author":"Hern\u00e1ndez-Conde","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib94","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/liv.14404","article-title":"The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease","volume":"40","author":"Scheiner","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jtha.2024.05.023_bib95","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jhep.2021.09.003","article-title":"EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis","volume":"76","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib96","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtha.2024.05.023_bib97","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtha.2024.05.023_bib98","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619888026","article-title":"Anticoagulation and transjugular intrahepatic portosystemic shunting for treatment of portal vein thrombosis in cirrhosis: a systematic review and meta-analysis","volume":"25","author":"Davis","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib99","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jceh.2022.12.016","article-title":"Anticoagulation for the treatment of portal vein thrombosis in cirrhosis: a systematic review and meta-analysis of comparative studies","volume":"13","author":"Yao","year":"2023","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib100","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221104797","article-title":"The efficacy and safety of anticoagulants in the treatment of cirrhotic portal vein thrombosis: a systematic review and meta-analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.05.023_bib101","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/hep.27783","article-title":"Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study","volume":"62","author":"Cerini","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2024.05.023_bib102","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2023.02.023","article-title":"Baveno Cooperation: an EASL consortium. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis","volume":"79","author":"Guerrero","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib103","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s10620-019-05572-z","article-title":"Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis","volume":"64","author":"Noronha Ferreira","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jtha.2024.05.023_bib104","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/tri.13353","article-title":"Mortality in liver transplant recipients with portal vein thrombosis - an updated meta-analysis","volume":"31","author":"Zanetto","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.jtha.2024.05.023_bib105","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2023.01.007","article-title":"Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis","volume":"78","author":"Fundora","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib106","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.clinre.2011.03.011","article-title":"The role of hypercoagulability in liver fibrogenesis","volume":"35","author":"Anstee","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jtha.2024.05.023_bib107","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0168-8278(23)00442-7","article-title":"Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial","volume":"78","author":"Sanchez","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib108","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.dld.2021.07.039","article-title":"Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: a systematic review and meta-analysis","volume":"54","author":"Koh","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jtha.2024.05.023_bib109","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MEG.0000000000001237","article-title":"A\u00a0prediction model for successful anticoagulation in cirrhotic portal vein thrombosis","volume":"31","author":"Rodriguez-Castro","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jtha.2024.05.023_bib110","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1478-3231.2012.02785.x","article-title":"Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal\u00a0vein thrombosis in cirrhosis","volume":"32","author":"Senzolo","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jtha.2024.05.023_bib111","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14309\/ajg.0000000000000486","article-title":"ACG clinical guideline: disorders of the hepatic and mesenteric circulation","volume":"115","author":"Simonetto","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jtha.2024.05.023_bib112","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII Faculty. Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T01:54:22Z","timestamp":1724378062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624003118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":112,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1538783624003118"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.05.023","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}